Last reviewed · How we verify
Active Iomazenil
Competitive antagonist of the central benzodiazepine receptor
Competitive antagonist of the central benzodiazepine receptor Used for Diagnostic imaging of brain disorders.
At a glance
| Generic name | Active Iomazenil |
|---|---|
| Sponsor | VA Office of Research and Development |
| Drug class | Benzodiazepine receptor antagonist |
| Target | Central benzodiazepine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 1 |
Mechanism of action
Iomazenil is a selective, non-benzodiazepine antagonist of the central benzodiazepine receptor, which is involved in the regulation of the GABA_A receptor.
Approved indications
- Diagnostic imaging of brain disorders
Common side effects
Key clinical trials
- Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans (PHASE1)
- GABA-glutamate Interactions and Psychosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |